Targets › FNTB
2 programs from 2 companies in 2 trials: 2 Phase 2; Oncology; next expected readout Sep 2027.
Essential subunit of the farnesyltransferase complex. Catalyzes the transfer of a farnesyl moiety from farnesyl diphosphate to a cysteine at the fourth position from the C-terminus of several proteins having the C-terminal sequence Cys-aliphatic-aliphatic-X. (UniProt, P49356)
Open in Phaseline: the race on FNTB, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| National Cancer Institute (NCI) | Tipifarnib Protein farnesyltransferase inhibitor | FNTA, FNTB | Phase 2 | Malignant Solid Neoplasm | Sep 2027 |
| Giselle Sholler | Tipifarnib Protein farnesyltransferase inhibitor | FNTA, FNTB | Phase 2 | Neuroblastoma | Dec 2030 |
Malignant Solid Neoplasm (1) Neuroblastoma (1)
small molecule (1), mixed (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.